Eli Lilly Files Lawsuits Over Illegal Retatrutide Market

Eli Lilly and Company is escalating its efforts to protect patients from the dangerous black market for retatrutide, having filed six new lawsuits in the United States. The pharmaceutical company aims to halt the sale of illegal and potentially harmful retatrutide products online.

The lawsuits target several online platforms that are allegedly facilitating the illicit distribution of illegally manufactured or counterfeit retatrutide products. Lilly has previously taken action against this illegal trade and is now expanding its enforcement.

The company is calling on online platforms, payment providers, and regulators to actively intervene in the illegal retatrutide trade. The objective is to prevent consumers from being exposed to potentially dangerous, unauthorized products that could pose significant health risks.

Retatrutide is a medication developed by Lilly for specific health conditions. The illegal black market poses a threat to patient safety and undermines confidence in the company's products. Lilly maintains its commitment to ensuring patient safety through these actions.